Blog

Bernard A. Fox: A new generation of immunotherapy clinical trials

Bernard Fox/LinkedIn

Jul 1, 2024, 17:27

Bernard A. Fox: A new generation of immunotherapy clinical trials

Bernard A. Fox, Co-Founder and CEO of UbiVac shared on LinkedIn:

“Great to be in Marseille with colleagues from Switzerland, Germany, Canada, and Singapore for the review of the Immunopole Pioneer Project efforts to cure patients of lung cancer. This 6 yr program has accumulated a wealth of blood and tissue biomarkers that are an incredible resource and will aid in the development of a new generation of immunotherapy clinical trials! BRAVO Fabrice Barlesi & the entire team who contributed to this effort. The meetings were held in what was Marseille’s 1st medical school Aix-Marseille Université (AMU) and overlook the Marina that will be the Paris 2024 International Olympic Committee – IOC sailing venue.”

Source: Bernard A. Fox/LinkedIn
.

Aix-Marseille Université AMU Bernard A. Fox biomarkers cancer cancer treatment clinical trials Fabrice Barlesi Immunopole Pioneer Project immunotherapy International collaboration Lung cancer Marseille OncoDaily Oncology oncology research Paris 2024 Olympics UbiVac

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer